Physician profile

Frank Riggall

Orlando, FL

NPI 1003895491

$1,103.70

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$92.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $370.20 2019-2020
Welch Allyn $230.40 2021
Pacira Pharmaceuticals Incorporated $100.00 2019
Gauss Surgical INC. $99.87 2019
Emd Serono, INC. $66.89 2019-2020
Organon LLC $59.14 2022-2023 Ganirelix Acetate, Follistim Aq, Pregnyl
Coopersurgical, INC. $57.68 2023 Stripper
Ferring Pharmaceuticals INC. $54.27 2019-2022
Merck Sharp & Dohme LLC $39.36 2019
Covidien LP $25.89 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Frank Riggall

$1,103.70

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/272481/frank-riggall

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.